Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Ocular Toxoplasma Retinochorioiditis: Clinical Presentation, Treatment Response and Outcome

Lie A., Callizo J., Metzner S., Hartmann C., Torun N., Pleyer U.
Dept. of Ophthalmology, Charité, Campus Virchow Hospital, Humboldt University of Berlin

Purpose: To present the clinical characteristics, diagnostic measures and treatment outcome in toxoplasma retinochorioiditis.
Method: In a consecutive series of 996 uveitis patients we identified 104 individuals with active ocular toxoplasmosis. All patients underwent a standard diagnostic protocol and if indicated, additional diagnostic tests such as aqueous humor analysis (n=74 patients). Data were analysed regarding clinical characteristics, presentation of ocular manifestation and treatment response following a standardized therapeutic approach. In addition, a subgroup of patients with central retinochoroidal lesions was followed by sequential visual field testing (n=24).
Results: All patients presented with an active toxoplasma retinochorioiditis of whom 47 (45%) had a recurrent manifestation. The mean age at onset of new or recurrent inflammatory lesions was 34 years. Our standardized initial treatment approach consisting of Clindamycin (4x600mg) was generally well tolerated but led to adverse effects in 7 patients (6.7%). Temporary applied Corticosteroids were necessary in 75 patients (73%) to control vitreous inflammation. In only 4 patients (3.8%) a combined treatment with Clindamycin/Pyremethamine had to be instilled because of unsatisfactory treatment response to monotherapy. Within a treatment period of 6.8


Zurück | Back